2017 KDIGO 慢性肾脏病-矿物质和骨异常指南更新执行摘要:变更内容与意义
该文是2017 KDIGO CKD-MBD指南更新的执行摘要,选择性更新2009版,面向成人及儿童CKD、透析或肾移植患者。文中强调更新推荐的理由,涉及骨异常诊断、降磷与钙维持、PTH异常治疗、抗骨吸收药物及肾移植骨病。
要点
- 更新涵盖CKD-MBD骨异常诊断、降磷保钙、PTH异常、骨质疏松治疗及移植骨病。
- 指南适用于成人及儿童CKD、慢性透析或肾移植患者。
- 更新为选择性更新,重点阐述对2009版推荐变更的依据。
核心结论
- 2017 KDIGO CKD-MBD指南是对2009版的选择性更新,重点阐释变更理由以辅助临床实践。
研究设计与样本
- 制定机构为KDIGO,方法为对2009版CKD-MBD指南进行选择性更新。
关键数值与推荐
- 推荐条款涉及CKD-MBD骨异常诊断、以降磷和维持钙为目标的治疗、PTH异常治疗、抗骨吸收药及其他骨质疏松治疗、肾移植骨病评估与治疗。
临床怎么用
- 用于指导成人及儿童CKD、慢性透析或肾移植患者的CKD-MBD诊疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD represents a selective update of the prior CKD-MBD Guideline published in 2009. This update, along with the 2009 publication, is intended to assist the practitioner caring for adults and children with chronic kidney disease (CKD), those on chronic dialysis therapy, or individuals with a kidney transplant. This review highlights key aspects of the 2017 CKD-MBD Guideline Update, with an emphasis on the rationale for the changes made to the original guideline document. Topic areas encompassing updated recommendations include diagnosis of bone abnormalities in CKD-mineral and bone disorder (MBD), treatment of CKD-MBD by targeting phosphate lowering and calcium maintenance, treatment of abnormalities in parathyroid hormone in CKD-MBD, treatment of bone abnormalities by antiresorptives and other osteoporosis therapies, and evaluation and treatment of kidney transplant bone disease.
引用
- Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int. 2017. PMID: 28646995. doi:10.1016/j.kint.2017.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。